MPN Watch

Dossier web other 11-jun-2026

EHA 2026: Key Blood Cancer Advances to Watch

Key claim: EHA 2026 will feature phase 3 SENTRY trial results evaluating selinexor plus ruxolitinib in myeloproliferative neoplasms.

Abstract

EHA 2026 will feature results from the phase 3 SENTRY trial, detailing the combination of selinexor plus ruxolitinib for patients with myeloproliferative neoplasms. Conference held in Stockholm, Sweden.

Why this matters

Pending synthesis.

Source

Link

Briefing card

EHA 2026: Key Blood Cancer Advances to Watch
Stage: other · web · 11-jun-2026

EHA 2026 will feature phase 3 SENTRY trial results evaluating selinexor plus ruxolitinib in myeloproliferative neoplasms.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://www.oncologynewscentral.com/hematologic-malignancies/blood-cancer-advances-to-watch-for-at-the-european-hematology-association-2026-congress

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11